Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 10:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

NCT01364974
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of ASP015K, Pharmacodynamics
Interventions
ASP015K, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 60 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2011 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Study of Bemnifosbuvir in Healthy Japanese Subjects

NCT05905497
View directory record Official record
Conditions
Healthy Volunteer Study
Interventions
Bemnifosbuvir (BEM)
Drug
Lead sponsor
Atea Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects

NCT03755778
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Itraconazole, Rifampin, Quinidine
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT07022119
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

NCT02207790
View directory record Official record
Conditions
Healthy Subjects
Interventions
E2609, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
30 Years to 60 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2015 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

NCT05406115
View directory record Official record
Conditions
Obesity
Interventions
AMG 786, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Tustin, California • Aventura, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 14, 2026, 10:34 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

NCT02696291
View directory record Official record
Conditions
Viral Infection
Interventions
UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of N6022 in Healthy Subjects

NCT01147406
View directory record Official record
Conditions
Healthy
Interventions
N6022, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

NCT01603147
View directory record Official record
Conditions
Methamphetamine Abuse
Interventions
normal saline, ch-mAb7f9
Biological
Lead sponsor
InterveXion Therapeutics, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.

NCT01290042
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
AMG 181, Placebo for AMG 181
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
5
States / cities
Glendale, California • Bridgeport, Connecticut • Danbury, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Characterize the Pharmacokinetics and Safety of TV-45070 Ointment in Healthy Volunteers

NCT02215941
View directory record Official record
Conditions
Pharmacokinetics
Interventions
TV-45070, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy Volunteers

NCT03146416
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Evinacumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of PF-06651600 in Subjects With Hepatic Impairment and Healthy Volunteers

NCT04016077
View directory record Official record
Conditions
Hepatic Impairment, Healthy Participants
Interventions
PF-06651600 30 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects

NCT01140672
View directory record Official record
Conditions
Healthy
Interventions
PF-04634817
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects

NCT01258777
View directory record Official record
Conditions
Healthy Volunteers
Interventions
400 mg golimumab or placebo, 200 mg golimumab or placebo
Drug
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Oct 14, 2026, 10:34 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase I, Multiple Dose Study of PF-04447943 in Healthy Elderly Volunteers

NCT00736528
View directory record Official record
Conditions
Healthy, Elderly
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 25, 2009 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Quizartinib Pharmacokinetics in Participants With Moderate Hepatic Impairment

NCT04473664
View directory record Official record
Conditions
Hepatic Impairment, Moderate Impaired Hepatic Function
Interventions
Quizartinib
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2023 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Test How BI 690517 is Taken up in the Body of People With and Without Liver Problems

NCT05731908
View directory record Official record
Conditions
Liver Diseases, Healthy
Interventions
BI 690517
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
2
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants

NCT03188783
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0853, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects

NCT03970122
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GFB-887, Placebo
Drug
Lead sponsor
Goldfinch Bio, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 2, 2020 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1607 MAD Study in Healthy Subjects

NCT01949103
View directory record Official record
Conditions
Infections, Bacterial Infections
Interventions
TD-1607, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects

NCT04091061
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers
Interventions
PF-06865571 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 14, 2026, 10:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sequential Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of TB006 in Healthy Subjects

NCT04920786
View directory record Official record
Conditions
Alzheimer Disease
Interventions
TB006, Sterile saline (Placebo)
Drug · Other
Lead sponsor
TrueBinding, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 14, 2026, 10:34 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetics, Safety, and Tolerability of ABBV-903 in Healthy Japanese and Han Chinese Participants

NCT06009237
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ABBV-903, Placebo for ABBV-903
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 14, 2026, 10:34 AM EDT